Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients with Active, R/R AML in the Phase 3 SIERRA Trial Stuart Seropian , Boglarka Gyurkocza , Rajneesh Nath , Hannah Choe , Mark Litzow , Camille Abboud , Nebu Koshy , Patrick Stiff , Benjamin Tomlinson , Sunil Abhyankar , James Foran , Sameem Abedin , George Chen , Zaid Al-Kadhimi , Partow Kebriaei , Mitchell Sabloff , Johnnie Orozco , Katarzyna Jamieson , Margarida Silverman , Koen Van Besien , Michael Schuster , Arjun Law , Sebastian Mayer , Hillard Lazarus , Jennifer Spross , Kate Li , Madhuri Vusirikala , Brenda Sandmaier , John Pagel , Avinash Desai , Sergio Giralt Clinical Lymphoma Myeloma and Leukemia（2024）
关键词
AML, relapsed/refractory, 131I-apamistamab, allogeneic stem cell transplant, radioimmunoconjugate, phase 3
AI 理解论文
溯源树
样例
